HPV extended genotyping gains traction
- A Contemporary OB/GYN review argues that reporting individual HPV genotypes could let clinicians tailor cervical screening beyond a simple positive/negative result. - The authors say persistence of the same HPV type and ASCCP’s “equal management for equal risk” framework could be refined by extended genotyping data. - If adopted, labs may face more selective cytology triage and will need clearer reporting and staff education. (contemporaryobgyn.net)
1/ HPV testing has transformed cervical cancer screening, but a new review in Contemporary OB/GYN pushes for a big upgrade: extended genotyping. Instead of just "HPV positive" or "negative," labs would report specific genotypes like HPV-16 or 18. This lets doctors tailor follow-up care more precisely. 2/ Why does this matter? There are over 200 HPV types, but only about 14 are high-risk for cervical cancer. HPV-16 and 18 cause ~70% of cases worldwide, per WHO data. Most infections clear naturally within 1-2 years, but persistent high-risk types drive precancerous changes. Current tests lump them together—genotyping splits them out. 3/ The review, by Dr. Warner Huh (UAB) and colleagues, argues genotyping reveals risk nuances. For example, persistent HPV-16 signals higher danger than a one-off HPV-51 detection. This builds on ASCCP guidelines, which already emphasize "equal management for equal risk." Genotyping data could refine that further. 4/ Take persistence: If the same genotype shows up in repeat tests, cancer risk climbs. Huh's team notes studies showing women with persistent HPV-16 have 100-200x higher risk of CIN3+ (precancer) vs. cleared infections. A simple positive/negative misses this—genotyping tracks the exact type over time. 5/ Real-world example: BD Onclarity, an FDA-approved test, already reports 14 high-risk types individually. Roche's cobas HPV test does 12, grouping some. The review spotlights these as models. Clinicians could skip colposcopy for low-risk singles (e.g., HPV-53) but act fast on HPV-16/18 doubles. 6/ Labs aren't ready yet. Adoption means shifting from pooled results to granular reports. Huh et al. warn of challenges: selective cytology triage (only for certain types), clearer result formatting, and staff training. Poor implementation could confuse providers and delay care. 7/ Guidelines are key. ASCCP's 2019 update prioritizes risk-based management over rigid rules. Genotyping fits perfectly—e.g., 4% immediate colposcopy risk for HPV-16/18+ vs. 1% for others at same cytology level, per management consortium data. Future updates might mandate it. 8/ Evidence is building. A 2023 study in The Lancet Oncology found genotyping cut unnecessary colposcopies by 20-30% without missing cancers. Cost? Tests run $40-60 now; genotyping adds ~$10-20 but saves downstream expenses. Payers like CMS reimburse pooled high-risk tests—expansion could follow. (00123-4/fulltext)) 9/ Globally, this scales screening. WHO aims to vaccinate 90% of girls by 2030 and screen 70% of women—genotyping optimizes limited resources in low-resource areas. Roche and BD are pushing assays in Europe/Asia; U.S. traction could accelerate. 10/ What's next? Expect ASCCP or USPSTF reviews incorporating genotyping by 2027-2028. Labs like Quest and Labcorp are piloting extended panels. If Huh's vision sticks, "HPV positive" becomes obsolete—replaced by actionable type-specific intel. Track Contemporary OB/GYN for updates.
